Preliminary findings of a probe initiated last year found that 2023 and 2024 revenue may have been overstated by “less than 2%” for each fiscal year, according to a Thursday
Shares in ICON fell as much as 50% on Thursday, their biggest intraday fall since March 30, 1999.
The Dublin-based company operates globally, providing clinical trials and commercialization advice to drug makers. In 2023, it announced a partnership ...
